This interview covers MIT professor Robert Langer's approach to turning scientific discoveries into profitable drugs. He says drug development is extremely long and expensive—averaging over $2 billion and 28 years, with very low success rates—so patents are essential to attract investment. He favors 'platform technology,' a foundational invention usable across multiple drugs, like his early slow-release polymer system. He stresses that business people are more critical than scientists, deciding which drug to pursue first and how to raise funds. Mentioned: Genentech (co-developed blockbuster Avastin), Avastin (approved in 2004, became one of the best-selling biotech drugs ever).
Professor Robert Langer is one of the most cited researchers in MIT history, specializing in the fields of drug delivery and tissue engineering. He has successfully combined theory with practice, becoming the core driving force behind the spin-off of multiple biotechnology companies from MIT. This d
Here is the translation of the Chinese investment research notes into English, strictly following all instructions.
Robert Langer is an MIT professor and one of the most cited researchers in history, specializing in drug delivery systems and tissue engineering. The main thread of this conversation is how to transform scientific discoveries into impactful commercial technologies, covering the entire chain from drug development processes and patent strategies to the key success factors for startups. Langer's core judgment is that in biotechnology, transforming a breakthrough discovery into a final approved drug typically takes 28 years, billions of dollars, and has an extremely low success rate—and this is precisely the fundamental reason for the existence of the "patent" mechanism.
Langer argues that the journey from discovering a molecule to becoming an approved drug is a lengthy process "measured in decades and costing billions of dollars," with clinical trials being the most expensive and uncertain step. He uses the example of angiogenesis inhibitors developed in collaboration with Judah Folkman to break down this chain in detail.
1. Historical Context and Scale: The paper on isolating the first angiogenesis inhibitors was published in 1976. However, the first drug based on this principle, Avastin, was not approved by the FDA until 28 years later in 2004. This drug later became one of the best-selling biotech drugs of all time, used for various cancers and eye diseases.
2. Mechanism and Cost Breakdown:
3. Uncertainty: Langer acknowledges that trials can fail even if results are perfect in animal models. "Proving that something new is safe and effective in humans is almost always the biggest expense."
Langer argues that the core of successful biotech spin-offs is not a single technology, but a "platform technology"—a fundamental invention that can be applied to multiple different drugs. He shares the formula for transforming lab results into multi-billion dollar companies.
1. Platform Technology Definition: An invention that can be used for "Drug A, B, C, D, E, etc." For example, the polymer system he invented early on for the slow release of large-molecule drugs is such a platform.
2. The "Two-Way" Role of Patents:
3. Importance of Business People: Langer emphasizes that business people are even more critical than the science itself. "If you look at the successful companies, it's because we had great business people. When companies didn't do well, it was usually because we didn't have good enough business people." Business people are responsible for: assessing market size, developing regulatory (FDA) and clinical trial strategies, managing the team, raising capital, and deciding which of the many applications of a "platform technology" to pursue first.
Langer believes that Artificial Intelligence's (AI) role in biotechnology is currently an "optimization tool," not a "revolutionary replacement." He is hopeful about the future but remains cautious.
1. AI Application Scenarios: Langer's most direct prediction is that AI can play a role in the early stages of drug discovery. For example, after high-throughput screening, AI can analyze tens of thousands of chemical structures, "looking at which ones worked, which ones didn't, finding commonalities, and then predicting what the next generation should test."
2. The Future of Tissue Engineering: In tissue engineering, Langer envisions "organs on a chip"—using chips to simulate human organs for more efficient drug testing with less reliance on animal experiments. He predicts that future "smart drug delivery systems" could be realized, such as a microchip that senses blood glucose levels and automatically releases insulin.
3. Cautious Time Horizon: Despite high hopes for AI and tissue engineering, Langer always emphasizes that "the future" could mean "hundreds of years from now." He explicitly states, "We still have a very long way to go." He tends to view progress as "incremental" rather than disruptive "leaps," although occasional breakthrough technologies like CRISPR do emerge.
This conversation is an in-depth interview and mentions almost no specific investable companies or position moves. The Genentech and Avastin mentioned by Langer serve as background cases to illustrate the long journey of drug development and do not constitute investment advice.
| Position | Speaker's Attitude | Key Data |
|---|---|---|
| Genentech | Background mention | Involved in the development of Avastin |
| Avastin | Background mention | Approved in 2004, became one of the best-selling biotech drugs of all time |
1. A PhD is a "license to fail" (Langer): A response to his early career experiences of numerous rejections and disapprovals. This is a scientist's version of "failure is the mother of success," but it emphasizes that failure is a systematic, expected process, not an endpoint. Support: His two initial discovery papers were rejected by Nature and Science respectively, but were eventually published.
2. New drug development is the "sorrow of financing" (Langer): Highlights the core contradiction of biotech investment—high returns must match extremely high failure rates and extremely long cycles. Support: "Developing a new drug costs over $2 billion, and only one in ten or one in twelve drugs ultimately succeeds."
3. "Choosing what to do first" is not just science (Langer): Faced with a "platform technology" applicable to many diseases, business decisions are more important than scientific intuition. Support: Decision criteria include: market size, availability of animal models, clarity of clinical trial endpoints, competitive landscape, reimbursement potential, and manufacturing difficulty.
4. AI in drug development is primarily an "optimization tool" (Langer): AI cannot replace creative experimentation but helps find patterns in large amounts of data to accelerate the next round of experimental design. Support: "If you use AI to analyze the chemical structures that worked and those that didn't, maybe you can predict what the next generation should test."
5. Patents are a "necessary condition for financing" (Langer): Points out the core economic function of the patent system in biotechnology—it is the only credible anchor for attracting capital. Support: "Without a patent, no one will give you $2 billion to develop a new drug."
6. Business people are more important than scientific discovery (Langer): Overturns the "science-led" narrative of entrepreneurship. Support: Langer directly attributes the success and failure of companies to whether they had "great business partners." "If you look at the successful companies, it's because we had great business people. When companies didn't do well, it was usually because we didn't have good enough business people."
7. "Drug accessibility in developing countries" is an under-capitalized direction (Langer): Suggests a significant market gap. Support: His lab is working with the Gates Foundation, aiming to reduce drug costs and distribute them to developing countries.
8. "Tissue engineering is still early, but skin has been approved" (Langer): Indicates that the field has reached a commercialization milestone, but "regenerating any organ" remains a distant future. Support: Artificial skin has been approved by the FDA for treating burn patients and diabetic skin ulcers, a miracle that has "already happened."